Beximco Pharma’s revenue outpaces major peers

Beximco Pharmaceuticals PLC reported a 13.1 percent year-on-year growth in its revenue in the first nine months of the 2025-26 financial year, outpacing its peers, according to an earnings update released by BRAC EPL Stock Brokerage.

The company recorded Tk 4,142 crore in net revenue during the July-March period of the 2025-26 financial year, up from Tk 3,662 crore a year earlier.

BRAC EPL Stock Brokerage Ltd said Square Pharma recorded a 12.5 percent year-on-year growth in revenue, while Renata posted more than 6.5 percent year-on-year growth in sales during the period.

“Domestic sales remained the primary growth driver, expanding 14.4 percent year-on-year. Export revenue grew a modest 1.2 percent in this financial year from a year ago,” said the firm in the update increased by 6.5 percent year-on-year.

BRAC EPL Stock Brokerage said this provided significant operating leverage to the company.